マーケットレポート詳細
羊膜製品の世界市場：羊膜タイプ別、用途別2028年予測
Amniotic Products Market by Type (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospital & Ambulatory Surgical Centers) - Global Forecast to 2028
- 出版元：MarketsandMarkets
出版元について - 発行年：2023年7月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文175ページになります。
- 商品コード：MAM3311
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
羊膜製品の世界市場規模は2023年で9億ドル、2028年に12億8900万ドル、市場の平均年成長率は7.4%になると予想されています。
レポートは羊膜製品の世界市場について2028年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（タイプ別市場、用途別市場、等）を中心に構成されています。また競合状況、主要企業情報（12社）、技術分析、特許分析などの分析も加味し、羊膜製品市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆羊膜製品の世界市場予測2021-2028年
・市場規模(US$)
◆羊膜タイプ別、市場-2028年
・凍結保存羊膜
・脱水羊膜
※(市場規模US$)
◆用途別、市場-2028年
・創傷ケア
・整形外科
・眼科
・その他用途
※(市場規模US$)
◆エンドユーザー別、市場-2028年
・病院/外来手術センター
・その他エンドユーザー
※(市場規模US$)
◆主要国地域別市場-2028年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・その他欧州
アジア太平洋
・日本、中国
・その他アジア太平洋
中南米
中東アフリカ
※地域別に全セグメントの細分化データ掲載、詳細は目次参照
※国別に各種セグメントの細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス（促進要因、障壁、機会、課題）
・プライシング分析
・サプライチェーン分析
・バリューチェーン分析
・エコシステム分析
・技術分析
・特許分析
・貿易分析
・業界構造分析
・競合状況
・市場シェア分析
◆羊膜製品の主要企業プロフィール動向
・MIMEDX GROUP, INC.
・SMITH+NEPHEW
・ORGANOGENESIS INC.
・INTEGRA LIFESCIENCES
・STRYKER
・APPLIED BIOLOGICS
・CELULARITY INC.
・CORZA OPHTHALMOLOGY
・LUCINA BIOSCIENCES
・NEXT BIOSCIENCES
・SKYE BIOLOGICS HOLDINGS, LLC
・SURGENEX
その他企業
・BIOTISSUE
・VENTRIS MEDICAL, LLC
・STIMLABS LLC
・VIVEX BIOLOGICS, INC.
・LIFECELL
・NUVISION BIOTHERAPIES LTD
・GENESIS BIOLOGICS, INC.
・SURGILOGIX
・TIDES MEDICAL
・ORTHOFIX US LLC
・ALLOSOURCE
・MERAKRIS THERAPEUTICS, INC.
・MTF BIOLOGICS
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS AND EXCLUSIONS 23
1.3 MARKET SCOPE 23
・ FIGURE 1 AMNIOTIC PRODUCTS MARKET SEGMENTATION 23
1.3.1 REGIONS CONSIDERED 24
1.3.2 YEARS CONSIDERED 24
1.4 CURRENCY CONSIDERED 25
1.5 STAKEHOLDERS 25
1.6 LIMITATIONS 25
1.7 RECESSION IMPACT 26
1.8 SUMMARY OF CHANGES 26
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA 27
・ FIGURE 2 AMNIOTIC PRODUCTS MARKET: RESEARCH DESIGN 27
2.2 SECONDARY DATA 27
2.2.1 SECONDARY SOURCES 28
2.3 PRIMARY DATA 29
・ FIGURE 3 PRIMARY SOURCES 30
2.3.1 KEY DATA FROM PRIMARY SOURCES 31
2.3.2 KEY INDUSTRY INSIGHTS 32
・ FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 32
2.4 MARKET SIZE ESTIMATION 33
・ FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 33
2.4.1 GROWTH FORECAST 34
・ FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 34
・ FIGURE 7 TOP-DOWN APPROACH 35
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 36
・ FIGURE 8 DATA TRIANGULATION METHODOLOGY 36
2.6 MARKET SHARE ANALYSIS 36
2.7 RESEARCH ASSUMPTIONS 37
2.8 RESEARCH LIMITATIONS 37
2.9 RISK ASSESSMENT 38
2.10 GROWTH RATE ASSUMPTIONS 38
2.11 RECESSION IMPACT ANALYSIS 38
3 EXECUTIVE SUMMARY
・ FIGURE 9 AMNIOTIC PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 39
・ FIGURE 10 AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 40
・ FIGURE 11 AMNIOTIC PRODUCTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 40
・ FIGURE 12 AMNIOTIC PRODUCTS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 41
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AMNIOTIC PRODUCTS MARKET 42
・ FIGURE 13 GROWING TARGET PATIENT POPULATION TO DRIVE MARKET 42
4.2 AMNIOTIC PRODUCTS MARKET, BY TYPE 43
・ FIGURE 14 CRYOPRESERVED AMNIOTIC MEMBRANES SEGMENT TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 43
4.3 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY TYPE AND COUNTRY 43
・ FIGURE 15 US ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2022 43
4.4 AMNIOTIC PRODUCTS MARKET, BY COUNTRY 44
・ FIGURE 16 US AND UK TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 44
5 MARKET OVERVIEW
5.1 INTRODUCTION 45
・ FIGURE 17 AMNIOTIC PRODUCTS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 45
5.2 MARKET DYNAMICS 45
5.2.1 DRIVERS 45
5.2.1.1 GROWTH IN TARGET PATIENT POPULATION 45
・ TABLE 1 GLOBAL PREVALENCE OF DIABETES 46
5.2.1.2 RISING INCIDENCE OF BURN INJURIES AND INCREASING NUMBER OF TRAUMATIC WOUNDS 47
5.2.1.3 WOUND CARE AWARENESS PROGRAMS AND INCREASING FUNDING FOR WOUND CARE TREATMENT AND MANAGEMENT 48
・ TABLE 2 WOUND CARE AWARENESS INITIATIVES 48
・ TABLE 3 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY NIH UNDER 21ST CENTURY CURES ACT 49
・ TABLE 4 FUNDING INITIATIVES FROM CORPORATE PARTNERSHIPS IN 2022 (USD MILLION) 49
・ TABLE 5 FUNDING FROM CORPORATE PARTNERSHIPS IN 2021 (USD MILLION) 50
・ FIGURE 18 ARTICLES RELATED TO AMNIOTIC PRODUCTS PUBLISHED DURING 2010–2021 50
5.2.1.4 INCREASING NUMBER OF AMNIOTIC MEMBRANE TRANSPLANTATIONS 51
・ TABLE 6 NUMBER OF AMNIOTIC MEMBRANE TRANSPLANTATIONS PERFORMED IN UNIVERSITY EYE HOSPITAL TÜBINGEN, GERMANY 51
5.2.1.5 INCREASING NUMBER OF OPHTHALMOLOGY, COSMETIC, AND ORTHOPEDIC SURGERIES 51
5.2.1.6 STRATEGIC COLLABORATIONS AND PARTNERSHIPS 52
5.2.1.7 FAVORABLE REIMBURSEMENT POLICIES 52
・ TABLE 7 MEDICARE ALLOWABLE AMOUNTS (USD) 52
5.2.2 OPPORTUNITIES 53
5.2.2.1 UNTAPPED OPPORTUNITIES IN EMERGING ECONOMIES 53
・ TABLE 8 STRATEGIC DEVELOPMENTS IN ASIA PACIFIC 54
5.2.2.2 IMPLEMENTATION OF 21ST CENTURY CURES ACT (US) 54
5.2.2.3 INCREASING DEMAND FOR STEM CELL RESEARCH AND REGENERATIVE MEDICINE 54
・ FIGURE 19 STEM CELL RESEARCH FUNDING FROM 2011 TO 2020 55
・ TABLE 9 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION) 55
5.2.3 CHALLENGES 56
5.2.3.1 COMPLICATIONS AND LIMITATIONS ASSOCIATED WITH USE OF AMNIOTIC MEMBRANES 56
5.2.3.2 ETHICAL AND LEGAL CONCERNS OF USING AMNIOTIC MEMBRANES 56
5.2.3.3 HIGH COST OF AMNIOTIC MEMBRANE PRODUCTS 57
5.2.3.4 COMPETITION FROM ALTERNATIVE THERAPIES 57
5.2.4 TRENDS 58
5.2.4.1 INCREASING CLINICAL TRIALS FOR STEM CELL AND CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPIES 58
5.2.4.2 EXPANDING APPLICATIONS AND RISING FOCUS ON STANDARDIZATION AND REGULATION OF AMNIOTIC PRODUCTS 58
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 59
5.3.1 REVENUE SHIFT AND REVENUE POCKETS FOR AMNIOTIC PRODUCT MANUFACTURERS 59
5.3.2 REVENUE SHIFT IN AMNIOTIC PRODUCTS MARKET 59
5.4 PRICING ANALYSIS 60
・ TABLE 10 PRICES OF AMNIOTIC PRODUCTS 60
5.5 SUPPLY CHAIN ANALYSIS 60
・ FIGURE 20 DIRECT DISTRIBUTION: STRATEGY PREFERRED BY PROMINENT COMPANIES 61
5.6 VALUE CHAIN ANALYSIS 61
・ FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING DEVELOPMENT PHASE 61
5.7 ECOSYSTEM ANALYSIS 62
5.7.1 ROLE IN ECOSYSTEM 62
・ TABLE 11 ROLE OF KEY PLAYERS IN ECOSYSTEM 62
・ FIGURE 22 KEY PLAYERS IN AMNIOTIC PRODUCTS ECOSYSTEM 63
5.8 TECHNOLOGY ANALYSIS 63
5.9 PATENT ANALYSIS 64
5.10 TRADE ANALYSIS 65
・ TABLE 12 IMPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND) 65
・ TABLE 13 EXPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND) 65
5.11 REGULATORY LANDSCAPE 66
5.11.1 NORTH AMERICA 66
5.11.2 EUROPE 66
5.11.3 EMERGING ECONOMIES 66
5.12 PORTER’S FIVE FORCES ANALYSIS 67
・ TABLE 14 AMNIOTIC PRODUCTS MARKET: IMPACT OF PORTER’S FIVE FORCES 67
5.12.1 INTENSITY OF COMPETITIVE RIVALRY 67
5.12.2 BARGAINING POWER OF SUPPLIERS 67
5.12.3 BARGAINING POWER OF BUYERS 68
5.12.4 THREAT OF SUBSTITUTES 68
5.12.5 THREAT OF NEW ENTRANTS 68
6 AMNIOTIC PRODUCTS MARKET, BY TYPE
6.1 INTRODUCTION 70
6.2 AMNIOTIC MEMBRANES 70
・ TABLE 15 AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 70
6.2.1 CRYOPRESERVED AMNIOTIC MEMBRANES 70
6.2.1.1 CRYOPRESERVED AMNIOTIC MEMBRANES TO DOMINATE AMNIOTIC MEMBRANES MARKET DURING FORECAST PERIOD 70
・ TABLE 16 CRYOPRESERVED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION) 72
6.2.2 DEHYDRATED AMNIOTIC MEMBRANES 72
6.2.2.1 LOGISTICAL ADVANTAGES OF DEHYDRATED AMNIOTIC MEMBRANES OVER CRYOPRESERVED AMNIOTIC MEMBRANES TO DRIVE DEMAND 72
・ TABLE 17 DEHYDRATED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION) 73
7 AMNIOTIC PRODUCTS MARKET, BY APPLICATION
7.1 INTRODUCTION 75
7.2 PRIMARY NOTES 75
・ TABLE 18 AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 75
7.3 WOUND CARE 76
7.3.1 RISING INCIDENCE OF ULCERS, TRAUMATIC AND SURGICAL WOUNDS, AND BURNS TO DRIVE MARKET 76
・ TABLE 19 AMNIOTIC PRODUCTS MARKET FOR WOUND CARE, BY REGION, 2021–2028 (USD MILLION) 77
7.4 ORTHOPEDICS 77
7.4.1 BENEFITS OFFERED BY AMNIOTIC PRODUCTS FOR ORTHOPEDIC APPLICATIONS TO DRIVE MARKET 77
・ TABLE 20 AMNIOTIC PRODUCTS MARKET FOR ORTHOPEDICS, BY REGION, 2021–2028 (USD MILLION) 78
7.5 OPHTHALMOLOGY 78
7.5.1 LIGHTWEIGHT, THIN, AND ELASTIC NATURE OF AMNIOTIC MEMBRANES TO DRIVE DEMAND IN OPHTHALMOLOGY 78
・ TABLE 21 AMNIOTIC PRODUCTS MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION) 79
7.6 OTHER APPLICATIONS 80
・ TABLE 22 ESTIMATED NUMBER OF COLORECTAL CANCER CASES AND DEATHS IN US IN 2020, BY AGE 80
・ TABLE 23 AMNIOTIC PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 81
8 AMNIOTIC PRODUCTS MARKET, BY END USER
8.1 INTRODUCTION 83
・ TABLE 24 AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 83
8.2 HOSPITALS & AMBULATORY SURGERY CENTERS 83
8.2.1 INCREASING NUMBER OF SURGICAL PROCEDURES TO DRIVE MARKET 83
・ TABLE 25 AMNIOTIC PRODUCTS MARKET FOR HOSPITALS & ASCS, BY REGION, 2021–2028 (USD MILLION) 85
8.3 OTHER END USERS 85
・ TABLE 26 AMNIOTIC PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 86
9 AMNIOTIC PRODUCTS MARKET, BY REGION
9.1 INTRODUCTION 88
・ TABLE 27 AMNIOTIC PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
9.2 NORTH AMERICA 88
・ FIGURE 23 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET SNAPSHOT 89
・ TABLE 28 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
・ TABLE 29 NORTH AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 90
・ TABLE 30 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 90
・ TABLE 31 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 91
9.2.1 US 91
9.2.1.1 GROWING GERIATRIC POPULATION AND HIGH PREVALENCE OF CHRONIC WOUNDS AND DIABETES TO DRIVE MARKET 91
・ TABLE 32 US: KEY MACRO INDICATORS 92
・ TABLE 33 US: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 92
・ TABLE 34 US: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 92
・ TABLE 35 US: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 93
9.2.2 CANADA 93
9.2.2.1 RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET 93
・ TABLE 36 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029 93
・ TABLE 37 CANADA: KEY MACRO INDICATORS 94
・ TABLE 38 CANADA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 94
・ TABLE 39 CANADA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 95
・ TABLE 40 CANADA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 95
9.2.3 RECESSION IMPACT ON NORTH AMERICA 95
9.3 EUROPE 96
・ TABLE 41 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP) 97
・ TABLE 42 PREVALENCE OF DIABETES IN EUROPE, 2019 VS. 2045 97
・ TABLE 43 EUROPE: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
・ TABLE 44 EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 98
・ TABLE 45 EUROPE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
・ TABLE 46 EUROPE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 99
9.3.1 GERMANY 99
9.3.1.1 INCREASING INCIDENCE OF DIABETES TO DRIVE MARKET 99
・ TABLE 47 GERMANY: KEY MACRO INDICATORS 100
・ TABLE 48 GERMANY: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 100
・ TABLE 49 GERMANY: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 101
・ TABLE 50 GERMANY: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 101
9.3.2 UK 101
9.3.2.1 HIGH PREVALENCE OF DIABETES ACTIVITIES TO DRIVE MARKET 101
・ TABLE 51 UK: KEY MACRO INDICATORS 102
・ TABLE 52 UK: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
・ TABLE 53 UK: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
・ TABLE 54 UK: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.3.3 FRANCE 103
9.3.3.1 GOVERNMENT SUPPORT TO DRIVE DEMAND FOR AMNIOTIC PRODUCTS 103
・ TABLE 55 FRANCE: KEY MACRO INDICATORS 104
・ TABLE 56 FRANCE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 104
・ TABLE 57 FRANCE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 105
・ TABLE 58 FRANCE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 105
9.3.4 REST OF EUROPE 105
・ TABLE 59 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP) 107
・ TABLE 60 REST OF EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
・ TABLE 61 REST OF EUROPE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
・ TABLE 62 REST OF EUROPE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 108
9.3.5 RECESSION IMPACT ON EUROPE 108
9.4 ASIA PACIFIC 108
・ FIGURE 24 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET SNAPSHOT 109
・ TABLE 63 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
・ TABLE 64 ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
・ TABLE 65 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
・ TABLE 66 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.4.1 CHINA 111
9.4.1.1 INCREASING INCIDENCE OF DIABETES AND GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET 111
・ TABLE 67 CHINA: KEY MACRO INDICATORS 112
・ TABLE 68 CHINA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
・ TABLE 69 CHINA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
・ TABLE 70 CHINA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.4.2 JAPAN 113
9.4.2.1 GROWING GERIATRIC POPULATION TO DRIVE MARKET 113
・ TABLE 71 JAPAN: KEY MACRO INDICATORS 114
・ TABLE 72 JAPAN: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
・ TABLE 73 JAPAN: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 114
・ TABLE 74 JAPAN: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 115
9.4.3 REST OF ASIA PACIFIC 115
・ TABLE 75 REST OF ASIA PACIFIC: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021 116
・ TABLE 76 REST OF ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 116
・ TABLE 77 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 117
・ TABLE 78 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 117
9.4.4 RECESSION IMPACT ON ASIA PACIFIC 117
9.5 LATIN AMERICA 118
9.5.1 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET 118
・ TABLE 79 LATIN AMERICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021 118
・ TABLE 80 LATIN AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
・ TABLE 81 LATIN AMERICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
・ TABLE 82 LATIN AMERICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 119
9.6 MIDDLE EAST & AFRICA 120
9.6.1 GROWTH IN HEALTHCARE INFRASTRUCTURE AND GOVERNMENT INITIATIVES TO DRIVE MARKET 120
・ TABLE 83 MIDDLE EAST & AFRICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021 121
・ TABLE 84 MIDDLE EAST & AFRICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
・ TABLE 85 MIDDLE EAST & AFRICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
・ TABLE 86 MIDDLE EAST & AFRICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 122
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 123
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 123
・ TABLE 87 OVERVIEW OF STRATEGIES ADOPTED BY KEY AMNIOTIC PRODUCT MARKET PLAYERS 123
10.3 MARKET SHARE ANALYSIS, 2022 124
・ TABLE 88 AMNIOTIC PRODUCTS MARKET: DEGREE OF COMPETITION (2022) 124
10.4 REVENUE SHARE ANALYSIS, 2022 125
・ FIGURE 25 AMNIOTIC PRODUCTS MARKET: REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS, 2020–2022 126
10.5 COMPANY EVALUATION QUADRANT 126
10.5.1 STARS 126
10.5.2 EMERGING LEADERS 126
10.5.3 PERVASIVE PLAYERS 126
10.5.4 PARTICIPANTS 127
・ FIGURE 26 AMNIOTIC PRODUCTS MARKET: COMPANY EVALUATION MATRIX, 2022 127
10.6 SMALL AND MEDIUM-SIZED ENTERPRISE/STARTUP EVALUATION QUADRANT 128
10.6.1 PROGRESSIVE COMPANIES 128
10.6.2 STARTING BLOCKS 128
10.6.3 RESPONSIVE COMPANIES 128
10.6.4 DYNAMIC COMPANIES 128
・ FIGURE 27 AMNIOTIC PRODUCTS MARKET: SMALL AND MEDIUM-SIZED ENTERPRISE/ STARTUP EVALUATION MATRIX, 2022 129
10.7 COMPETITIVE BENCHMARKING 129
・ TABLE 89 AMNIOTIC PRODUCTS MARKET: DETAILED LIST OF KEY SMALL AND MEDIUM-SIZED ENTERPRISES/STARTUPS 129
10.8 COMPETITIVE SCENARIO 130
10.8.1 PRODUCT LAUNCHES 130
・ TABLE 90 PRODUCT LAUNCHES 130
10.8.2 DEALS 130
・ TABLE 91 DEALS 130
10.8.3 OTHERS 131
・ TABLE 92 OTHERS 131
10.9 COMPANY FOOTPRINT ANALYSIS 132
・ TABLE 93 COMPANY FOOTPRINT ANALYSIS 132
・ TABLE 94 COMPANY PRODUCT FOOTPRINT 133
・ TABLE 95 COMPANY REGIONAL FOOTPRINT 134
11 COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS/SOLUTIONS/SERVICES OFFERED, RECENT DEVELOPMENTS, MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, WEAKNESS/COMPETITIVE THREATS)*
11.1 KEY PLAYERS 135
11.1.1 MIMEDX GROUP, INC. 135
・ TABLE 96 MIMEDX GROUP, INC.: COMPANY OVERVIEW 135
・ FIGURE 28 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022) 136
11.1.2 SMITH+NEPHEW 139
・ TABLE 97 SMITH+NEPHEW: COMPANY OVERVIEW 139
・ FIGURE 29 SMITH+NEPHEW: COMPANY SNAPSHOT (2022) 140
11.1.3 ORGANOGENESIS INC. 142
・ TABLE 98 ORGANOGENESIS INC.: COMPANY OVERVIEW 142
・ FIGURE 30 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022) 142
11.1.4 INTEGRA LIFESCIENCES 145
・ TABLE 99 INTEGRA LIFESCIENCES: COMPANY OVERVIEW 145
・ FIGURE 31 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022) 146
11.1.5 STRYKER 149
・ TABLE 100 STRYKER: COMPANY OVERVIEW 149
・ FIGURE 32 STRYKER: COMPANY SNAPSHOT (2022) 150
11.1.6 APPLIED BIOLOGICS 152
・ TABLE 101 APPLIED BIOLOGICS: COMPANY OVERVIEW 152
11.1.7 CELULARITY INC. 153
・ TABLE 102 CELULARITY INC.: COMPANY OVERVIEW 153
11.1.8 CORZA OPHTHALMOLOGY 154
・ TABLE 103 CORZA OPHTHALMOLOGY: COMPANY OVERVIEW 154
11.1.9 LUCINA BIOSCIENCES 155
・ TABLE 104 LUCINA BIOSCIENCES: COMPANY OVERVIEW 155
11.1.10 NEXT BIOSCIENCES 156
・ TABLE 105 NEXT BIOSCIENCES: COMPANY OVERVIEW 156
11.1.11 SKYE BIOLOGICS HOLDINGS, LLC 157
・ TABLE 106 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW 157
11.1.12 SURGENEX 158
・ TABLE 107 SURGENEX: COMPANY OVERVIEW 158
11.2 OTHER PLAYERS 159
11.2.1 BIOTISSUE 159
11.2.2 VENTRIS MEDICAL, LLC 160
11.2.3 STIMLABS LLC 161
11.2.4 VIVEX BIOLOGICS, INC. 162
11.2.5 LIFECELL 163
11.2.6 NUVISION BIOTHERAPIES LTD 164
11.2.7 GENESIS BIOLOGICS, INC. 165
11.2.8 SURGILOGIX 166
11.2.9 TIDES MEDICAL 167
11.2.10 ORTHOFIX US LLC 168
11.2.11 ALLOSOURCE 169
11.2.12 MERAKRIS THERAPEUTICS, INC. 170
11.2.13 MTF BIOLOGICS 171
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS/SOLUTIONS/SERVICES OFFERED, RECENT DEVELOPMENTS, MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, WEAKNESS/COMPETITIVE THREATS)* MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.